When Every Breath
Becomes a Struggle
There may be options beyond antifibrotics alone.
"I used to walk for miles. Now I get breathless crossing the room."
Regenerative treatments using mesenchymal stem cells (MSCs) are being studied for their potential to reduce lung inflammation and slow fibrotic progression — offering realistic hope for improved quality of life.
The Reality of Living with IPF
Idiopathic pulmonary fibrosis doesn't just steal your breath — it steals your life. The simple pleasures that once brought joy become exhausting ordeals. Walking to the mailbox feels like climbing a mountain. Conversations are interrupted by breathlessness.
Current antifibrotic medications like pirfenidone and nintedanib can slow progression, but many people continue to decline. The oxygen concentrator becomes a constant companion, the portable tanks a reminder of limitations.
"Every morning I wonder: will today be the day I need more oxygen? Will I make it to my grandchild's graduation?"
But research is revealing new possibilities. Mesenchymal stem cells are being studied for their anti-inflammatory and anti-fibrotic properties — offering a complementary approach that may help slow decline and improve daily comfort.
The Harsh Reality of IPF
Why guests and families are seeking additional options
- Median survival of 3-5 years from diagnosis without treatment
- Antifibrotics slow but don't stop progression for most guests
- Progressive oxygen dependency impacts independence
- Lung transplant — the only "cure" — is available to very few
Regenerative medicine offers a different approach — targeting the inflammatory and fibrotic processes at their source rather than just managing symptoms.
Why the Lungs Scar — And Why They Struggle to Heal
In IPF, the normal wound-healing process goes into overdrive. Microscopic injuries to the lung epithelium trigger a cascade of inflammation and fibroblast activation that never resolves. Instead of healing, the lung lays down more and more scar tissue.
This fibrotic tissue is stiff and thick — it can't exchange oxygen like healthy lung tissue. Over time, the scarring spreads, breathing becomes harder, and oxygen levels drop.
- Epithelial cell injury triggers abnormal repair response
- TGF-β signaling becomes dysregulated, driving fibrosis
- Myofibroblasts deposit excessive collagen
- The lung loses elasticity and gas exchange capacity
Why MSCs Are Being Studied
Mesenchymal stem cells have immunomodulatory and anti-fibrotic properties. In preclinical studies, they've been shown to reduce inflammation, inhibit fibroblast activation, and potentially slow scar tissue formation.
Read William's Full Story"After two years of watching my FVC drop steadily, I needed to try something beyond my daily pills. Six months after the infusions, my numbers have stabilized for the first time. I can walk my dog again without stopping every few steps. That's everything to me."
*Name changed for privacy. Photo may feature a model. Individual results may vary.
What the Research Shows
Early-phase clinical trials have focused on safety and feasibility. While larger Phase III trials are ongoing, initial results are encouraging.
Forced Vital Capacity (FVC) Decline Comparison
% of Baseline FVC Over Time
Based on Glassberg et al. AETHER trial, Chest (2017), doi:10.1016/j.chest.2016.10.016
Glassberg et al. (2017)
Chest, AETHER Phase I
AETHER Phase I safety clinical trial: single IV infusion of allogeneic human MSCs in IPF patients was safe with no treatment-related serious adverse events.
9 patients
DOI: 10.1016/j.chest.2016.10.016 PMID: 29653694
Moodley et al. (2009)
Am J Pathol
UC-MSCs reduced fibrosis in bleomycin-induced lung injury model, demonstrating anti-fibrotic and anti-inflammatory mechanisms relevant to IPF.
Preclinical
Toonkel et al. (2013)
Am J Respir Crit Care Med
Comprehensive review of MSC potential for IPF clinical testing, establishing the scientific rationale for Phase I trials and optimal delivery methods.
Review
Understanding Your Options
Regenerative therapy is designed to complement — not replace — standard care
Important: We recommend continuing your current medications. MSC therapy is being studied as an adjunctive approach, not a replacement for proven treatments.
Is Regenerative Therapy Right for You?
The medical team at our partner clinics evaluates each guest individually to ensure the best possible outcomes
May Be a Good Candidate
Guests who may benefit most from MSC evaluation:
- Diagnosed IPF or confirmed pulmonary fibrosis
- FVC above 40% predicted (mild-moderate disease)
- Stable on current medications
- No active lung infections
- Motivated to explore complementary approaches
- Understand realistic expectations vs. cure
May Not Be Ideal
Guests who may need alternative approaches:
- Very advanced disease (FVC below 40%)
- Active pulmonary hypertension
- Awaiting imminent lung transplant
- Active cancer or serious infection
Your Treatment Journey
Arrival & Comprehensive Assessment
Pulmonary function tests, 6-minute walk test, blood work, and specialist consultation to establish your baseline and personalize your protocol.
MSC Infusion Protocol
IV administration of mesenchymal stem cells in a comfortable clinical setting. Each session includes monitoring and respiratory therapy support.
Recovery & Education
Light activity, breathing exercises, and detailed guidance on follow-up care. The Sterling team ensures you're comfortable before returning home.
Progress Assessment
Follow-up pulmonary function testing to track any changes. Many guests report improved comfort and exercise tolerance by this milestone.
Realistic Treatment Goals
We believe in honest expectations. MSC therapy is not a cure for IPF, but research suggests it may help:
- Slow or stabilize lung function decline
- Reduce shortness of breath during daily activities
- Improve exercise tolerance and quality of life
- Potentially reduce inflammation in lung tissue
Looking for More Tomorrows?
If you're living with IPF and wondering whether regenerative medicine might help slow your decline and improve your daily comfort, our pulmonary specialists are here to help you understand your options.
Your $5,999 Discovery includes a $5,000 credit toward any program — making your net investment just $999.
Individual results may vary. MSC therapy for IPF is investigational and not FDA-approved as a treatment. Consult with your pulmonologist before making any treatment decisions.